RxDoctor Payments Data

Talal Alnabelsi, MD

Cardiovascular Disease · Lexington, KYNPI 1467869180

Payments from drug & device makers

$1,348in general payments, 2019–2025

Across 14 payments — averaging $96.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$552
  • Abbott$402
  • Philips North America LLC$135
  • Medtronic$114
  • Pfizer$101
  • Astellas Pharma US Inc$24
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$96472%
  • Education$38428%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,348 in reported general payments places this provider in the 30th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$55,226
Medicare patients
469
Services billed
761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$148,467
JardianceEmpagliflozin70$86,638
Repatha SureclickEvolocumab35$27,516
FarxigaDapagliflozin Propanediol24$24,756
EntrestoSacubitril/Valsartan22$23,795
XareltoRivaroxaban21$20,378
Praluent PenAlirocumab12$9,504
Cinacalcet Hcl13$3,473
Metoprolol Succinate117$1,444
Atorvastatin Calcium98$1,225
Amlodipine-ValsartanAmlodipine Besylate/Valsartan24$1,044
Valsartan30$951
Rosuvastatin Calcium95$861
Ezetimibe32$534
Carvedilol75$527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$101$148,467130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →